Sarah Boyce, President and CEO at Avidity Biosciences, Inc. (RNA), sold 100 shares at $22.47 ($2K) on 2022-08-15, disclosed to the SEC on 2022-08-17.
Scheduled sale ($2k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RNA | SELL | 2025-09-05 | $2.5M | — | Filing → |
| RNA | SELL | 2025-08-29 | $1.2M | — | Filing → |
| RNA | SELL | 2025-03-21 | $2.0M | — | Filing → |